New indication criteria: better availability of GLP1 receptor agonists for our patients

Česká verzia

Authors: Zbynek Schroner
Authors place of work: Lekárska fakulta, Univerzita Pavla Jozefa Šafárika v Košiciach
Published in the journal: Diab Obez 2023; 23(45): 61-62
Category: News

Štítky

Diabetology Obesitology

Článek Quo vadis, slovenská diabetológia?

Článek The dual GIP and GLP1 receptor agonist tirzepatide: a new effective treatment for type 2 diabetes mellitus

Článek Diabetes mellitus and options for early prevention of heart failure

Článek Evaluation of the current situation and possibilities in the management of obesity in Slovakia

Článek Ceramides and cardiovascular disease

Článek Social services in diabetes mellitus

Článek Practical experience with dapagliflozin: case reports

Článek The patient with type 2 diabetes is hemodynamically and metabolically stable, despite treatment, the progression of chronic kidney disease proceeds. What other options do we have? A case report

Článek Empagliflozin in patients with chronic kidney disease: results of the EMPA-KIDNEY trial and implications for clinical practice

Článek The head-to-head comparison of insulin glargine 300 units/ml and degludec 100 units/ml using the CGM technology: results of the InRange trial

Článek The SGLT2 inhibitor canagliflozin: benefits in the treatment of type 2 diabetes mellitus

Článek Spomienka na MUDr. Blaženu Dyskovú

Článek A glimpse into the 13th chamber – overt and covert manifestations of diabetes mellitus

Článek World Diabetes Congress, Lisabon 2022

Článek Advanced Technologies & Treatments for Diabetes 2023, Berlín

Článek 5th National SDS Symposium: How are we doing with technology in diabetology in Slovakia and what new things do we expect in the future?

Článok vyšiel v časopise

Diabetes and obesity

2023 Číslo 45

Najčítanejšie tento týždeň

The Importance of Hydration in Wound Healing

Najčítanejšie v tomto čísle